CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: RINL (ImmuneEditome ID:126432)

1. Gene summary of enriched editing regions for RINL

check button Gene summary
Gene informationGene symbol

RINL

Gene ID

126432

GeneSynonyms-
GeneCytomap

19q13.2

GeneTypeprotein-coding
GeneDescriptionras and Rab interactor-like protein
GeneModificationdate20230329
UniprotIDQ6ZS11;M0QZ15
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr19:38868014-38869116:-ENST00000591812.1ENSG00000187994.12RINLexonicL2a,AluJr,AluJo,MER33,AluSpchr19:38868014-38869116:-.alignment
chr19:38868014-38869116:-ENST00000598904.4ENSG00000187994.12RINLexonicL2a,AluJr,AluJo,MER33,AluSpchr19:38868014-38869116:-.alignment


Top

2. Tumor-specific enriched editing regions for RINL


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr19:38868014-38869116:-BRCAEER4.3136e-03image
ENSG00000187994.12,RINLBRCAEAG4.3136e-03image
chr19:38868014-38869116:-LIHCEER2.5429e-02image
ENSG00000187994.12,RINLLIHCEAG2.5252e-02image
chr19:38868014-38869116:-LUADEER7.7630e-04image
ENSG00000187994.12,RINLLUADEAG7.7630e-04image
chr19:38868014-38869116:-UCECEER7.4821e-03image
ENSG00000187994.12,RINLUCECEAG7.4135e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr19:38868014-38869116:-BLCAPathEER4.2047e-021.2872e-020.1518image
ENSG00000187994.12,RINLBLCAPathEAG4.2047e-021.2872e-020.1518image
chr19:38868014-38869116:-KIRCPathEER7.3580e-046.8318e-050.1719image
ENSG00000187994.12,RINLKIRCPathEAG7.3580e-046.8318e-050.1719image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr19:38868014-38869116:-LGGEER3.7941e-021.2801e-021.5437e-02image
ENSG00000187994.12,RINLLGGEAG3.7941e-021.2801e-021.5437e-02image

Top

3. Enriched editing regions and immune related genes for RINL


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:38868014-38869116:-COADEERENSG00000187994,RINL-0.44046.1628e-083.2802e-12-0.4527imageNELAVL1;HNRNPC;HNRNPK;ILF3;NOP56;NOP58;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_BILE_ACID_METABOLISM
chr19:38868014-38869116:-UCECEERENSG00000187994,RINL-0.45815.8855e-054.2029e-07-0.4016imageNELAVL1;HNRNPC;HNRNPK;ILF3;NOP56;NOP58;U2AF2NAMast_cells_restingGSVA_HALLMARK_ANGIOGENESIS
chr19:38868014-38869116:-ESCAEERENSG00000197646,PDCD1LG20.43242.5985e-041.0728e-070.4240imageNELAVL1;IGF2BP2PDCD1LG2Macrophages_M1GSVA_HALLMARK_ALLOGRAFT_REJECTION
chr19:38868014-38869116:-ESCAEERENSG00000187994,RINL-0.42412.6841e-041.4701e-09-0.4758imageNELAVL1;HNRNPC;HNRNPK;ILF3;NOP56;NOP58;U2AF2NAB_cells_naiveGSVA_HALLMARK_HYPOXIA
chr19:38868014-38869116:-OVEERENSG00000187994,RINL-0.54771.6758e-162.9603e-13-0.4255imageNELAVL1;HNRNPC;HNRNPK;ILF3;NOP56;NOP58;U2AF2NAT_cells_CD8GSVA_HALLMARK_NOTCH_SIGNALING
chr19:38868014-38869116:-UVMEERENSG00000091073,DTX20.50521.5162e-032.7429e-060.5207imageNDDX54;DGCR8;ELAVL1;HNRNPC;HNRNPK;IGF2BP2;ILF3;NOP58;U2AF2NAT_cells_CD8GSVA_HALLMARK_P53_PATHWAY
chr19:38868014-38869116:-UVMEERENSG00000211895,IGHA10.42291.1212e-021.4820e-040.4325imageNNIGHA1Macrophages_M1GSVA_HALLMARK_ALLOGRAFT_REJECTION
chr19:38868014-38869116:-UVMEERENSG00000187994,RINL-0.39041.3692e-023.9672e-04-0.4064imageNELAVL1;HNRNPC;HNRNPK;ILF3;NOP56;NOP58;U2AF2NAT_cells_CD4_memory_activatedGSVA_HALLMARK_KRAS_SIGNALING_DN
chr19:38868014-38869116:-UVMEERENSG00000160446,ZDHHC120.40331.4713e-022.9886e-040.4141imageNDDX54;DGCR8;HNRNPK;IGF2BP2;NOP58NAT_cells_CD4_memory_restingGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr19:38868014-38869116:-UVMEERENSG00000071859,FAM50A0.39621.8337e-021.8488e-060.5283imageNDDX54;DGCR8;ELAVL1;HNRNPC;HNRNPK;IGF2BP2;ILF3;NOP56;NOP58;U2AF2NAT_cells_CD8GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr19:38868014-38869116:-COADEERENSG00000187994,RINL-0.44046.1628e-083.2802e-12-0.4527imageNELAVL1;HNRNPC;HNRNPK;ILF3;NOP56;NOP58;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_BILE_ACID_METABOLISM
chr19:38868014-38869116:-UCECEERENSG00000187994,RINL-0.45815.8855e-054.2029e-07-0.4016imageNELAVL1;HNRNPC;HNRNPK;ILF3;NOP56;NOP58;U2AF2NAMast_cells_restingGSVA_HALLMARK_ANGIOGENESIS
chr19:38868014-38869116:-ESCAEERENSG00000197646,PDCD1LG20.43242.5985e-041.0728e-070.4240imageNELAVL1;IGF2BP2PDCD1LG2Macrophages_M1GSVA_HALLMARK_ALLOGRAFT_REJECTION
chr19:38868014-38869116:-ESCAEERENSG00000187994,RINL-0.42412.6841e-041.4701e-09-0.4758imageNELAVL1;HNRNPC;HNRNPK;ILF3;NOP56;NOP58;U2AF2NAB_cells_naiveGSVA_HALLMARK_HYPOXIA
chr19:38868014-38869116:-OVEERENSG00000187994,RINL-0.54771.6758e-162.9603e-13-0.4255imageNELAVL1;HNRNPC;HNRNPK;ILF3;NOP56;NOP58;U2AF2NAT_cells_CD8GSVA_HALLMARK_NOTCH_SIGNALING
chr19:38868014-38869116:-UVMEERENSG00000091073,DTX20.50521.5162e-032.7429e-060.5207imageNDDX54;DGCR8;ELAVL1;HNRNPC;HNRNPK;IGF2BP2;ILF3;NOP58;U2AF2NAT_cells_CD8GSVA_HALLMARK_P53_PATHWAY
chr19:38868014-38869116:-UVMEERENSG00000211895,IGHA10.42291.1212e-021.4820e-040.4325imageNNIGHA1Macrophages_M1GSVA_HALLMARK_ALLOGRAFT_REJECTION
chr19:38868014-38869116:-UVMEERENSG00000187994,RINL-0.39041.3692e-023.9672e-04-0.4064imageNELAVL1;HNRNPC;HNRNPK;ILF3;NOP56;NOP58;U2AF2NAT_cells_CD4_memory_activatedGSVA_HALLMARK_KRAS_SIGNALING_DN
chr19:38868014-38869116:-UVMEERENSG00000160446,ZDHHC120.40331.4713e-022.9886e-040.4141imageNDDX54;DGCR8;HNRNPK;IGF2BP2;NOP58NAT_cells_CD4_memory_restingGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr19:38868014-38869116:-UVMEERENSG00000071859,FAM50A0.39621.8337e-021.8488e-060.5283imageNDDX54;DGCR8;ELAVL1;HNRNPC;HNRNPK;IGF2BP2;ILF3;NOP56;NOP58;U2AF2NAT_cells_CD8GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

More results



Top

4. Enriched editing regions and immune related splicing for RINL


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000187994.12,RINL
ESCAEAGIRENSG00000163755.4chr3149167033:149167240:149167888:1491679830.35283.2839e-039.8543e-060.4184imageNADAR;BUD13;CNBP;CSTF2T;DDX3X;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP3;KHDRBS1;KHDRBS2;LIN28A;LIN28B;LSM11;MOV10;MSI2;NOP56;NOP58;PCBP2;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM27;SAFB2;SF3A3;SF3B4;SMNDC1;SND1;SRSF1;SRSF9;TAF15;TNRC6A;TROVE2;U2AF1;U2AF2;UPF1;XRN2HPS3Mast_cells_activatedGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE
chr19:38868014-38869116:-
ESCAEERIRENSG00000163755.4chr3149167033:149167240:149167888:1491679830.35073.2498e-031.2512e-050.4140imageNDDX54;DGCR8;DHX9;ELAVL1;HNRNPC;HNRNPK;IGF2BP2;NOP56;NOP58;U2AF2HPS3Mast_cells_activatedGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE
ENSG00000187994.12,RINL
ESCAEAGESENSG00000112414.10chr6142381950:142382019:142383759:142383843:142390257:142390343-0.34221.8098e-032.2475e-07-0.4756imageNADAR;BCCIP;BUD13;CNBP;CSTF2T;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP3;KHDRBS2;KHDRBS3;LIN28A;LIN28B;MOV10;NOP56;NOP58;PCBP2;PRPF8;PTBP1;QKI;RBFOX2;RBM10;SF3A3;SF3B4;SMNDC1;SND1;SRSF1;SRSF9;TAF15;TROVE2;U2AF1;U2AF2;UPF1NAMacrophages_M1GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION
chr19:38868014-38869116:-
ESCAEERESENSG00000112414.10chr6142381950:142382019:142383759:142383843:142390257:142390343-0.34621.3088e-032.0162e-07-0.4773imageNDDX54;DGCR8;DHX9;ELAVL1;HNRNPC;HNRNPK;IGF2BP2;NOP56;NOP58;U2AF2NAMacrophages_M1GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION
chr19:38868014-38869116:-
GBMEERIRENSG00000187994.9chr1938867829:38869166:38869246:38869410-0.33962.7793e-031.1767e-08-0.4560imageNELAVL1;HNRNPC;HNRNPK;ILF3;NOP56;NOP58;U2AF2NAMonocytesGSVA_HALLMARK_MYC_TARGETS_V1
ENSG00000187994.12,RINL
GBMEAGIRENSG00000187994.9chr1938867829:38869166:38869246:38869410-0.33963.2304e-031.1767e-08-0.4560imageNADAR;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;LIN28A;LIN28B;LSM11;MOV10;MSI2;NOP56;NOP58;PCBP2;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM27;SAFB2;SF3A3;SF3B4;SMNDC1;SND1;SRSF1;SRSF9;TAF15;TNRC6A;TROVE2;U2AF1;U2AF2;UPF1;XRN2NAMonocytesGSVA_HALLMARK_MYC_TARGETS_V1
chr19:38868014-38869116:-
TGCTEERIRENSG00000125459.10chr1155746795:155746935:155747128:155747183-0.30415.3122e-038.9718e-06-0.4076imageNDDX54;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;U2AF2NAB_cells_memoryGSVA_HALLMARK_UV_RESPONSE_DN
ENSG00000187994.12,RINL
TGCTEAGIRENSG00000164867.6chr7151012350:151012472:151013230:151013378-0.40455.6186e-047.2360e-07-0.4004imageNADAR;BCCIP;BUD13;CPSF6;CSTF2T;DDX3X;DDX42;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP3;ILF3;KHDRBS1;LIN28B;LSM11;MSI2;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RBFOX2;RBM27;SAFB2;SF3B4;SMNDC1;SND1;SRSF1;SRSF9;TAF15;TNRC6A;TROVE2;U2AF1;U2AF2;XRN2NOS3Macrophages_M2GSVA_HALLMARK_MTORC1_SIGNALING
ENSG00000187994.12,RINL
TGCTEAGA3ENSG00000138162.13chr10122211685:122211708:122215402:122215451:122215390:1222154510.21384.7967e-021.4584e-070.4354imageNADAR;BCCIP;BUD13;CNBP;CSTF2T;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP3;KHDRBS1;KHDRBS3;LIN28A;LIN28B;MOV10;NOP56;NOP58;PCBP2;PRPF8;PTBP1;QKI;RBFOX2;RBM10;SF3A3;SF3B4;SMNDC1;SND1;SRSF1;SRSF9;TAF15;TROVE2;U2AF1;U2AF2;UPF1NAMacrophages_M2GSVA_HALLMARK_PANCREAS_BETA_CELLS
ENSG00000187994.12,RINL
TGCTEAGIRENSG00000125459.10chr1155746795:155746935:155747128:155747183-0.30414.6142e-038.9718e-06-0.4076imageNADAR;BCCIP;BUD13;CNBP;CSTF2T;DDX42;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPK;IGF2BP3;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RBM10;SF3A3;SF3B4;SMNDC1;SND1;SRSF1;TAF15;U2AF1;U2AF2;UPF1NAB_cells_memoryGSVA_HALLMARK_UV_RESPONSE_DN

More results



Top

5. Enriched editing regions and immune infiltration for RINL


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr19:38868014-38869116:-ACCEEREosinophils9.1560e-060.6814image
ENSG00000187994.12,RINLACCEAGEosinophils9.1560e-060.6814image
chr19:38868014-38869116:-BLCAEERT_cells_regulatory_(Tregs)1.5216e-03-0.1924image
ENSG00000187994.12,RINLBLCAEAGT_cells_regulatory_(Tregs)1.5216e-03-0.1924image
chr19:38868014-38869116:-BRCAEERT_cells_CD82.4347e-04-0.1136image
ENSG00000187994.12,RINLBRCAEAGT_cells_CD82.4347e-04-0.1136image
chr19:38868014-38869116:-CESCEERB_cells_naive9.2099e-03-0.1540image
ENSG00000187994.12,RINLCESCEAGB_cells_naive9.2340e-03-0.1540image
chr19:38868014-38869116:-COADEERMonocytes3.4731e-03-0.1989image
ENSG00000187994.12,RINLCOADEAGMonocytes3.4731e-03-0.1989image
chr19:38868014-38869116:-ESCAEERT_cells_regulatory_(Tregs)2.0817e-03-0.2536image
ENSG00000187994.12,RINLESCAEAGT_cells_regulatory_(Tregs)2.1387e-03-0.2530image
chr19:38868014-38869116:-GBMEERT_cells_CD4_naive1.6008e-020.1890image
ENSG00000187994.12,RINLGBMEAGT_cells_CD4_naive1.6008e-020.1890image
chr19:38868014-38869116:-HNSCEERT_cells_follicular_helper6.2809e-03-0.1497image
ENSG00000187994.12,RINLHNSCEAGT_cells_follicular_helper6.7429e-03-0.1484image
chr19:38868014-38869116:-KIRCEERDendritic_cells_resting1.3066e-050.2204image
ENSG00000187994.12,RINLKIRCEAGDendritic_cells_resting1.3066e-050.2204image
chr19:38868014-38869116:-KIRPEERB_cells_naive1.4001e-020.1519image
ENSG00000187994.12,RINLKIRPEAGB_cells_naive1.4001e-020.1519image
chr19:38868014-38869116:-LAMLEERMacrophages_M24.9951e-02-0.2096image
ENSG00000187994.12,RINLLAMLEAGMacrophages_M24.9951e-02-0.2096image
chr19:38868014-38869116:-LGGEERT_cells_CD4_naive3.6135e-040.2171image
ENSG00000187994.12,RINLLGGEAGT_cells_CD4_naive3.6135e-040.2171image
chr19:38868014-38869116:-LIHCEERMacrophages_M18.5968e-050.2142image
ENSG00000187994.12,RINLLIHCEAGMacrophages_M18.7519e-050.2139image
chr19:38868014-38869116:-LUADEERDendritic_cells_activated6.3128e-030.1237image
ENSG00000187994.12,RINLLUADEAGDendritic_cells_activated6.3128e-030.1237image
chr19:38868014-38869116:-LUSCEERPlasma_cells1.6627e-02-0.1148image
ENSG00000187994.12,RINLLUSCEAGPlasma_cells1.6627e-02-0.1148image
chr19:38868014-38869116:-OVEERMacrophages_M12.5700e-030.1831image
ENSG00000187994.12,RINLOVEAGMacrophages_M12.7344e-030.1820image
chr19:38868014-38869116:-PAADEERNK_cells_resting1.3768e-050.3213image
ENSG00000187994.12,RINLPAADEAGNK_cells_resting1.3768e-050.3213image
chr19:38868014-38869116:-PCPGEERMacrophages_M15.3613e-030.2067image
ENSG00000187994.12,RINLPCPGEAGMacrophages_M15.3613e-030.2067image
chr19:38868014-38869116:-PRADEERMast_cells_activated3.8750e-020.1118image
ENSG00000187994.12,RINLPRADEAGMast_cells_activated3.8750e-020.1118image
chr19:38868014-38869116:-READEERNeutrophils3.8239e-020.2307image
ENSG00000187994.12,RINLREADEAGNeutrophils3.8239e-020.2307image
chr19:38868014-38869116:-SARCEERMacrophages_M11.6710e-020.1748image
ENSG00000187994.12,RINLSARCEAGMacrophages_M11.6710e-020.1748image
chr19:38868014-38869116:-SKCMEERT_cells_CD82.9963e-020.1042image
ENSG00000187994.12,RINLSKCMEAGT_cells_CD82.9963e-020.1042image
chr19:38868014-38869116:-STADEERT_cells_CD81.2712e-020.1372image
ENSG00000187994.12,RINLSTADEAGT_cells_CD81.4908e-020.1339image
chr19:38868014-38869116:-TGCTEERMacrophages_M23.4219e-040.2924image
ENSG00000187994.12,RINLTGCTEAGMacrophages_M23.4219e-040.2924image
chr19:38868014-38869116:-THYMEERMast_cells_resting9.3755e-060.3954image
ENSG00000187994.12,RINLTHYMEAGMast_cells_resting9.3755e-060.3954image
chr19:38868014-38869116:-UCECEERNK_cells_activated2.9086e-020.1794image
ENSG00000187994.12,RINLUCECEAGNK_cells_activated2.9142e-020.1794image
chr19:38868014-38869116:-UCSEERPlasma_cells1.4231e-050.5672image
ENSG00000187994.12,RINLUCSEAGPlasma_cells1.4231e-050.5672image
chr19:38868014-38869116:-UVMEERNK_cells_activated3.2099e-020.2529image
ENSG00000187994.12,RINLUVMEAGNK_cells_activated3.2099e-020.2529image


Top

6. Enriched editing regions and immune gene sets for RINL


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr19:38868014-38869116:-BLCAEER6.7974e-060.27052.0549e-020.14123.0381e-060.28021.5808e-050.2599image
ENSG00000187994.12,RINLBLCAEAG6.7974e-060.27052.0549e-020.14123.0381e-060.28021.5808e-050.2599image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000187994.12,RINLACCGSVA_HALLMARK_PROTEIN_SECRETIONEAG2.2483e-020.3903image
chr19:38868014-38869116:-ACCGSVA_HALLMARK_PROTEIN_SECRETIONEER2.2483e-020.3903image
chr19:38868014-38869116:-BLCAGSVA_HALLMARK_APICAL_JUNCTIONEER4.7900e-060.2748image
ENSG00000187994.12,RINLBLCAGSVA_HALLMARK_APICAL_JUNCTIONEAG4.7900e-060.2748image
ENSG00000187994.12,RINLBRCAGSVA_HALLMARK_GLYCOLYSISEAG2.4585e-100.1947image
chr19:38868014-38869116:-BRCAGSVA_HALLMARK_GLYCOLYSISEER2.4585e-100.1947image
chr19:38868014-38869116:-CESCGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER2.2414e-040.2169image
ENSG00000187994.12,RINLCESCGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG2.2719e-040.2167image
chr19:38868014-38869116:-CHOLGSVA_HALLMARK_PROTEIN_SECRETIONEER1.7390e-020.4176image
ENSG00000187994.12,RINLCHOLGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.7390e-020.4176image
ENSG00000187994.12,RINLCOADGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG3.1490e-020.1471image
chr19:38868014-38869116:-COADGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER3.1490e-020.1471image
ENSG00000187994.12,RINLDLBCGSVA_HALLMARK_APICAL_SURFACEEAG6.4264e-040.4752image
chr19:38868014-38869116:-DLBCGSVA_HALLMARK_APICAL_SURFACEEER6.4264e-040.4752image
chr19:38868014-38869116:-ESCAGSVA_HALLMARK_PEROXISOMEEER8.1069e-05-0.3214image
ENSG00000187994.12,RINLESCAGSVA_HALLMARK_PEROXISOMEEAG7.3471e-05-0.3232image
chr19:38868014-38869116:-GBMGSVA_HALLMARK_DNA_REPAIREER2.3068e-03-0.2378image
ENSG00000187994.12,RINLGBMGSVA_HALLMARK_DNA_REPAIREAG2.3068e-03-0.2378image
chr19:38868014-38869116:-HNSCGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER2.2494e-080.3009image
ENSG00000187994.12,RINLHNSCGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG1.5702e-080.3041image
ENSG00000187994.12,RINLKICHGSVA_HALLMARK_P53_PATHWAYEAG3.2770e-020.2694image
chr19:38868014-38869116:-KIRPGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER8.0851e-040.2061image
ENSG00000187994.12,RINLKIRPGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG8.0851e-040.2061image
chr19:38868014-38869116:-LAMLGSVA_HALLMARK_PANCREAS_BETA_CELLSEER4.5598e-03-0.2997image
ENSG00000187994.12,RINLLAMLGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG4.5598e-03-0.2997image
ENSG00000187994.12,RINLLGGGSVA_HALLMARK_ANGIOGENESISEAG1.4312e-07-0.3158image
chr19:38868014-38869116:-LGGGSVA_HALLMARK_ANGIOGENESISEER1.4312e-07-0.3158image
ENSG00000187994.12,RINLLIHCGSVA_HALLMARK_BILE_ACID_METABOLISMEAG9.1069e-100.3285image
chr19:38868014-38869116:-LIHCGSVA_HALLMARK_BILE_ACID_METABOLISMEER8.9354e-100.3286image
ENSG00000187994.12,RINLLUADGSVA_HALLMARK_HYPOXIAEAG7.8770e-060.2011image
chr19:38868014-38869116:-LUADGSVA_HALLMARK_HYPOXIAEER7.8770e-060.2011image
ENSG00000187994.12,RINLLUSCGSVA_HALLMARK_UV_RESPONSE_UPEAG3.3153e-030.1405image
chr19:38868014-38869116:-LUSCGSVA_HALLMARK_UV_RESPONSE_UPEER3.3153e-030.1405image
ENSG00000187994.12,RINLMESOGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG6.8545e-030.3182image
chr19:38868014-38869116:-MESOGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER6.8545e-030.3182image
ENSG00000187994.12,RINLOVGSVA_HALLMARK_BILE_ACID_METABOLISMEAG9.0741e-050.2364image
chr19:38868014-38869116:-OVGSVA_HALLMARK_BILE_ACID_METABOLISMEER8.4136e-050.2374image
ENSG00000187994.12,RINLPAADGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG1.0390e-020.1927image
chr19:38868014-38869116:-PAADGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER1.0390e-020.1927image
chr19:38868014-38869116:-PCPGGSVA_HALLMARK_ANGIOGENESISEER3.5628e-040.2632image
ENSG00000187994.12,RINLPCPGGSVA_HALLMARK_ANGIOGENESISEAG3.5628e-040.2632image
chr19:38868014-38869116:-PRADGSVA_HALLMARK_HYPOXIAEER4.7667e-030.1523image
ENSG00000187994.12,RINLPRADGSVA_HALLMARK_HYPOXIAEAG4.7667e-030.1523image
chr19:38868014-38869116:-READGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.4517e-030.3321image
ENSG00000187994.12,RINLREADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.4517e-030.3321image
chr19:38868014-38869116:-SARCGSVA_HALLMARK_KRAS_SIGNALING_DNEER6.1802e-03-0.1996image
ENSG00000187994.12,RINLSARCGSVA_HALLMARK_KRAS_SIGNALING_DNEAG6.1802e-03-0.1996image
ENSG00000187994.12,RINLSKCMGSVA_HALLMARK_UV_RESPONSE_UPEAG6.3026e-040.1635image
chr19:38868014-38869116:-SKCMGSVA_HALLMARK_UV_RESPONSE_UPEER6.3026e-040.1635image
ENSG00000187994.12,RINLSTADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG7.3261e-050.2165image
chr19:38868014-38869116:-STADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER3.2678e-050.2269image
ENSG00000187994.12,RINLTGCTGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG2.1386e-04-0.3018image
chr19:38868014-38869116:-TGCTGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER2.1386e-04-0.3018image
ENSG00000187994.12,RINLTHYMGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG1.4683e-050.3874image
chr19:38868014-38869116:-THYMGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER1.4683e-050.3874image
ENSG00000187994.12,RINLUCECGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG4.7722e-030.2308image
chr19:38868014-38869116:-UCECGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER4.5428e-030.2320image
ENSG00000187994.12,RINLUVMGSVA_HALLMARK_COAGULATIONEAG1.9503e-030.3591image
chr19:38868014-38869116:-UVMGSVA_HALLMARK_COAGULATIONEER1.9503e-030.3591image


Top

7. Enriched editing regions and drugs for RINL


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr19:38868014-38869116:-ACCLenalidomideEER8.4049e-030.4447image
ENSG00000187994.12,RINLACCLenalidomideEAG8.4049e-030.4447image
chr19:38868014-38869116:-BLCAEHT.1864EER6.3562e-070.2981image
ENSG00000187994.12,RINLBLCAEHT.1864EAG6.3562e-070.2981image
ENSG00000187994.12,RINLBRCAKIN001.135EAG4.9909e-09-0.1801image
chr19:38868014-38869116:-BRCAKIN001.135EER4.9909e-09-0.1801image
chr19:38868014-38869116:-CESCCI.1040EER1.2750e-02-0.1474image
ENSG00000187994.12,RINLCESCCI.1040EAG1.2738e-02-0.1474image
ENSG00000187994.12,RINLCOADEHT.1864EAG1.7138e-020.1628image
chr19:38868014-38869116:-COADEHT.1864EER1.7138e-020.1628image
ENSG00000187994.12,RINLDLBCKIN001.135EAG7.8389e-04-0.4685image
chr19:38868014-38869116:-DLBCKIN001.135EER7.8389e-04-0.4685image
chr19:38868014-38869116:-ESCAEHT.1864EER6.8686e-040.2787image
ENSG00000187994.12,RINLESCAEHT.1864EAG9.9412e-040.2706image
ENSG00000187994.12,RINLGBMAICAREAG3.6160e-04-0.2769image
chr19:38868014-38869116:-GBMAICAREER3.6160e-04-0.2769image
chr19:38868014-38869116:-HNSCLFM.A13EER1.0849e-09-0.3266image
ENSG00000187994.12,RINLHNSCLFM.A13EAG1.7713e-09-0.3226image
ENSG00000187994.12,RINLKICHGemcitabineEAG4.2007e-02-0.2570image
chr19:38868014-38869116:-KIRCAS601245EER6.2440e-050.2028image
ENSG00000187994.12,RINLKIRCAS601245EAG6.2440e-050.2028image
chr19:38868014-38869116:-KIRPBAY.61.3606EER4.9209e-050.2485image
ENSG00000187994.12,RINLKIRPBAY.61.3606EAG4.9209e-050.2485image
chr19:38868014-38869116:-LAMLGDC0941EER8.1656e-04-0.3504image
ENSG00000187994.12,RINLLAMLGDC0941EAG8.1656e-04-0.3504image
ENSG00000187994.12,RINLLGGCGP.60474EAG8.4916e-060.2692image
chr19:38868014-38869116:-LGGCGP.60474EER8.4916e-060.2692image
ENSG00000187994.12,RINLLIHCBleomycinEAG1.1098e-080.3093image
chr19:38868014-38869116:-LIHCBleomycinEER1.1260e-080.3092image
chr19:38868014-38869116:-LUADLFM.A13EER5.2621e-03-0.1264image
ENSG00000187994.12,RINLLUADLFM.A13EAG5.2621e-03-0.1264image
ENSG00000187994.12,RINLLUSCBMS.754807EAG1.4125e-04-0.1815image
chr19:38868014-38869116:-LUSCBMS.754807EER1.4125e-04-0.1815image
chr19:38868014-38869116:-MESOAG.014699EER2.0120e-03-0.3605image
ENSG00000187994.12,RINLMESOAG.014699EAG2.0120e-03-0.3605image
ENSG00000187994.12,RINLOVBIBW2992EAG4.2256e-03-0.1739image
chr19:38868014-38869116:-OVBIBW2992EER3.8737e-03-0.1755image
ENSG00000187994.12,RINLPAADATRAEAG1.6909e-020.1835image
chr19:38868014-38869116:-PAADATRAEER1.6909e-020.1835image
chr19:38868014-38869116:-PCPGABT.263EER9.4245e-050.2869image
ENSG00000187994.12,RINLPCPGABT.263EAG9.4245e-050.2869image
ENSG00000187994.12,RINLPRADAZD.0530EAG6.3122e-03-0.1487image
chr19:38868014-38869116:-PRADAZD.0530EER6.3122e-03-0.1487image
ENSG00000187994.12,RINLSARCEpothilone.BEAG5.1966e-040.2514image
chr19:38868014-38869116:-SARCEpothilone.BEER5.1966e-040.2514image
ENSG00000187994.12,RINLSKCMBicalutamideEAG3.8492e-07-0.2408image
chr19:38868014-38869116:-SKCMBicalutamideEER3.8492e-07-0.2408image
ENSG00000187994.12,RINLSTADBX.795EAG4.3658e-05-0.2230image
chr19:38868014-38869116:-STADBX.795EER1.1121e-04-0.2115image
ENSG00000187994.12,RINLTGCTMethotrexateEAG4.6009e-090.4614image
chr19:38868014-38869116:-TGCTMethotrexateEER4.6009e-090.4614image
ENSG00000187994.12,RINLTHCAEmbelinEAG9.8264e-030.1149image
chr19:38868014-38869116:-THCAEmbelinEER9.8264e-030.1149image
chr19:38868014-38869116:-THYMCytarabineEER7.5695e-090.5010image
ENSG00000187994.12,RINLTHYMCytarabineEAG7.5695e-090.5010image
chr19:38868014-38869116:-UCECBIRB.0796EER4.9394e-020.1618image
ENSG00000187994.12,RINLUCECBIRB.0796EAG4.8994e-020.1621image
chr19:38868014-38869116:-UCSCCT018159EER5.7742e-03-0.3813image
ENSG00000187994.12,RINLUCSCCT018159EAG5.7742e-03-0.3813image
chr19:38868014-38869116:-UVMCGP.60474EER3.5498e-04-0.4094image
ENSG00000187994.12,RINLUVMCGP.60474EAG3.5498e-04-0.4094image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType